Emerging Infectious Diseases is an open access, peer-reviewed journal published monthly by the Centers for Disease Control and Prevention (CDC). The journal was established expressly to promote the recognition of new and reemerging infectious diseases around the world and to improve the understanding of factors involved in disease emergence, prevention, and elimination.
Emerging Infectious Diseases is intended for professionals in infectious diseases and related sciences. The journal welcomes contributions from infectious disease specialists in academia, industry, clinical practice, and public health, as well as from specialists in economics, social sciences, and other disciplines. Manuscripts in all categories should explain the contents in public health terms.
Emerging Infectious Diseases began publishing online only with the January 2020 issue. Volumes 1–25 of the journal also were printed on acid-free paper that meets the requirements of ANSI/NISO Z39.48-1984 (Permanence of Paper). Those issues might not contain certain graphics and figures, color images, technical appendices, videos, and other online-only content.
In all instances, CDC publishes the official version of record of the journal online. Publication in EID enables compliance with the NIH Public Access Policy.
Emerging Infectious Diseases follows the International Committee of Medical Journal Editors recommendations for the conduct, reporting, editing, and publishing of scholarly work in medical journals. The journal’s peer review process allows for critical assessment of submitted manuscripts by experts who are usually not part of its editorial staff, and it operates independently from CDC’s clearance processes.
The conclusions, findings, and opinions expressed by authors contributing to Emerging Infectious Diseases do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by the Public Health Service or by the U.S. Department of Health and Human Services.
EMERGING INFECTIOUS DISEASES® is a registered service mark of the U.S. Department of Health and Human Services. Its Registration Number 4,972,553 is issued by the United States Patent & Trademark Office (USPTO).
Open Access and Usage/Copyright
Emerging Infectious Diseases is an open access journal published by the Centers for Disease Control and Prevention, a U.S. Government agency. The journal is a member in good standing of the Directory of Open Access Journals.
All materials published in Emerging Infectious Diseases, including text, figures, tables, and photographs, are in the public domain and can be reprinted or used without permission with proper citation. All content is freely available without charge to the user or their institution. In accordance with the Budapest Open Access Initiative definition of open access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. Because the journal is in the public domain, its usage policy also conforms to conditions set forth by Creative Commons.
Any written work prepared by employees of the federal government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available.
Emerging Infectious Diseases does request a proper citation be included for its content and that any changes made to any content be clearly indicated. Suggested citation wording is included with each article.
Emerging Infectious Diseases grants authors permission to self-archive their articles without fees or permission and grants institutions permission to preserve a second copy of articles published by their researchers in the institutional repository.
Archiving Full-Text Content and Abstracts
Full-text content of Emerging Infectious Diseases is digitally archived each month and available via PubMed Central.
Full abstracts for all articles and online reports, including EID’s Early Release content, are accessible via PubMed.gov.
Each article contains a digital object identifier (DOI) link to the original, complete article on the EID website.
Peer Review Process Overview
The peer review process for Emerging Infectious Diseases is managed via an online editorial system (Manuscript Central). EID operates a single-blind peer review system, in which the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.
The Editor-in-Chief screens submissions, rejects unsuitable manuscripts, and assigns articles deemed appropriate for peer review to associate editors or members of the editorial board. Manuscripts accepted for peer review will generally be reviewed by experts who are provided with a copy of the manuscript, author checklist, and associated files, such as graphics or technical appendices. Those reviewers evaluate whether the manuscript is scientifically sound and has public health utility. The associate editors or members of the editorial board evaluate peer reviewers' recommendations and send their decision to the Editor-in-Chief, who has the final decision on accepting or rejecting manuscripts.
Emerging Infectious Diseases follows the ICMJE recommendations for Protection of Research Participants.
In brief, when studies involve human participants, authors are responsible for including a statement that those studies have been approved by the appropriate institutional or national research ethics committee and have been performed in accordance with the ethical standards noted in the 1964 Declaration of Helsinki and its later amendments or comparable ethics standards.
In brief, when reporting experiments on animals, authors should indicate whether institutional and national standards for the care and use of laboratory animals were followed.
Emerging Infectious Diseases reserves the right to request that authors provide documentation from the review board or ethics committee confirming approval of the research.
Impact Factor (Journal Citation Reports)
EID’s 2021 impact factor is 16.162, 4th among open-access infectious disease journals and 9th among the 94 tracked infectious disease journals. EID’s impact factor indicates that articles published in the journal during the last 2 years have been cited an average of more than 16 times during the past year.
Google Scholar h-Index
- 2022 h5-index: 106; h5-median:173
- Ranked 2nd of top 20 publications in Epidemiology and 2nd among open-access journals
- Ranked 4th among top 20 publications in Communicable Diseases and 1st among open-access journals.
Scopus CiteScore Metrics for Serials
- 2021 EID CiteScore = 13
- Ranked 24th out of 295 infectious diseases journals (92nd percentile)–3rd ranked open-access journal
- Ranked 11th out of 118 microbiology journals (91st percentile)–3rd ranked open-access journal
- Ranked 10th out of 108 epidemiology infectious diseases journals (91st percentile)–6th ranked open-access journal
Submissions and Acceptance
- Emerging Infectious Diseases receives more than 2,000 manuscripts per year (most unsolicited, some invited) from authors around the world.
- Approximately 25% of submitted articles are accepted.
- > 70,000 subscribers to table of contents emails (subscribe here)
- > 900,000 total recipients to EID’s email notifications
- More than 17 million page visits to EID’s website in 2020 (CDC Web Statistics)
- More than 8.8 million views in 2020 for EID’s articles in PubMed Central
Contact us for additional information.